 | • レポートコード：MRC23Q36298 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、88ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の原発性卵巣機能不全治療市場について調査・分析し、世界の原発性卵巣機能不全治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他）、用途別セグメント分析（20歳以下、20～30歳、30～45歳、45歳以上）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Bayer、Novartis、Bioscience Institute、Johns Hopkins Medicine、Mayo Clinic、Baptist Health、Indira IVFなどが含まれています。世界の原発性卵巣機能不全治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、原発性卵巣機能不全治療市場規模を推定する際に考慮しました。本レポートは、原発性卵巣機能不全治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、原発性卵巣機能不全治療に関するビジネス上の意思決定に役立てることを目的としています。 ・原発性卵巣機能不全治療市場の概要 - 原発性卵巣機能不全治療のタイプ別セグメント - 世界の原発性卵巣機能不全治療市場規模：タイプ別分析（ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他） - 原発性卵巣機能不全治療の用途別セグメント - 世界の原発性卵巣機能不全治療市場規模：用途別分析（20歳以下、20～30歳、30～45歳、45歳以上） - 世界の原発性卵巣機能不全治療市場規模予測（2018年-2029年） ・原発性卵巣機能不全治療市場の成長トレンド - 原発性卵巣機能不全治療の地域別市場規模（2018年-2029年） - 原発性卵巣機能不全治療市場ダイナミクス - 原発性卵巣機能不全治療の業界動向 - 原発性卵巣機能不全治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他 - 世界の原発性卵巣機能不全治療のタイプ別市場規模（2018年-2023年） - 世界の原発性卵巣機能不全治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：20歳以下、20～30歳、30～45歳、45歳以上 - 世界の原発性卵巣機能不全治療の用途別市場規模（2018年-2023年） - 世界の原発性卵巣機能不全治療の用途別市場規模（2024年-2029年） ・原発性卵巣機能不全治療の地域別市場規模 - 北米の原発性卵巣機能不全治療市場規模（2018年-2029年） - アメリカの原発性卵巣機能不全治療市場規模（2018年-2029年） - ヨーロッパの原発性卵巣機能不全治療市場規模（2018年-2029年） - アジア太平洋の原発性卵巣機能不全治療市場規模（2018年-2029年） - 中国の原発性卵巣機能不全治療市場規模（2018年-2029年） - 日本の原発性卵巣機能不全治療市場規模（2018年-2029年） - 韓国の原発性卵巣機能不全治療市場規模（2018年-2029年） - インドの原発性卵巣機能不全治療市場規模（2018年-2029年） - オーストラリアの原発性卵巣機能不全治療市場規模（2018年-2029年） - 中南米の原発性卵巣機能不全治療市場規模（2018年-2029年） - 中東・アフリカの原発性卵巣機能不全治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer、Bayer、Novartis、Bioscience Institute、Johns Hopkins Medicine、Mayo Clinic、Baptist Health、Indira IVF ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Primary Ovarian Insufficiency Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Primary Ovarian Insufficiency Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Primary Ovarian Insufficiency Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Primary Ovarian Insufficiency Therapy in Less than 20 Years Old is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Primary Ovarian Insufficiency Therapy include Pfizer, Bayer, Novartis, Bioscience Institute, Johns Hopkins Medicine, Mayo Clinic, Baptist Health and Indira IVF, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Ovarian Insufficiency Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Ovarian Insufficiency Therapy.
The Primary Ovarian Insufficiency Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Primary Ovarian Insufficiency Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Ovarian Insufficiency Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Bayer
Novartis
Bioscience Institute
Johns Hopkins Medicine
Mayo Clinic
Baptist Health
Indira IVF
Segment by Type
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Others
Segment by Application
Less than 20 Years Old
20 to 30 Years Old
30 to 45 Years Old
45 Years Old and Older
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Primary Ovarian Insufficiency Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hormone Replacement Therapy (HRT)
1.2.3 Calcium and Vitamin D Supplements
1.2.4 In Vitro Fertilization (IVF)
1.2.5 Stem Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Primary Ovarian Insufficiency Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Less than 20 Years Old
1.3.3 20 to 30 Years Old
1.3.4 30 to 45 Years Old
1.3.5 45 Years Old and Older
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Ovarian Insufficiency Therapy Market Perspective (2018-2029)
2.2 Primary Ovarian Insufficiency Therapy Growth Trends by Region
2.2.1 Global Primary Ovarian Insufficiency Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Primary Ovarian Insufficiency Therapy Historic Market Size by Region (2018-2023)
2.2.3 Primary Ovarian Insufficiency Therapy Forecasted Market Size by Region (2024-2029)
2.3 Primary Ovarian Insufficiency Therapy Market Dynamics
2.3.1 Primary Ovarian Insufficiency Therapy Industry Trends
2.3.2 Primary Ovarian Insufficiency Therapy Market Drivers
2.3.3 Primary Ovarian Insufficiency Therapy Market Challenges
2.3.4 Primary Ovarian Insufficiency Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Ovarian Insufficiency Therapy Players by Revenue
3.1.1 Global Top Primary Ovarian Insufficiency Therapy Players by Revenue (2018-2023)
3.1.2 Global Primary Ovarian Insufficiency Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Primary Ovarian Insufficiency Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Ovarian Insufficiency Therapy Revenue
3.4 Global Primary Ovarian Insufficiency Therapy Market Concentration Ratio
3.4.1 Global Primary Ovarian Insufficiency Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Ovarian Insufficiency Therapy Revenue in 2022
3.5 Primary Ovarian Insufficiency Therapy Key Players Head office and Area Served
3.6 Key Players Primary Ovarian Insufficiency Therapy Product Solution and Service
3.7 Date of Enter into Primary Ovarian Insufficiency Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Ovarian Insufficiency Therapy Breakdown Data by Type
4.1 Global Primary Ovarian Insufficiency Therapy Historic Market Size by Type (2018-2023)
4.2 Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Type (2024-2029)
5 Primary Ovarian Insufficiency Therapy Breakdown Data by Application
5.1 Global Primary Ovarian Insufficiency Therapy Historic Market Size by Application (2018-2023)
5.2 Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
6.2 North America Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
6.4 North America Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
7.2 Europe Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
7.4 Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
8.2 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
9.2 Latin America Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
9.4 Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
10.2 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Primary Ovarian Insufficiency Therapy Introduction
11.1.4 Pfizer Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Primary Ovarian Insufficiency Therapy Introduction
11.2.4 Bayer Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.2.5 Bayer Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Primary Ovarian Insufficiency Therapy Introduction
11.3.4 Novartis Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Bioscience Institute
11.4.1 Bioscience Institute Company Detail
11.4.2 Bioscience Institute Business Overview
11.4.3 Bioscience Institute Primary Ovarian Insufficiency Therapy Introduction
11.4.4 Bioscience Institute Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.4.5 Bioscience Institute Recent Development
11.5 Johns Hopkins Medicine
11.5.1 Johns Hopkins Medicine Company Detail
11.5.2 Johns Hopkins Medicine Business Overview
11.5.3 Johns Hopkins Medicine Primary Ovarian Insufficiency Therapy Introduction
11.5.4 Johns Hopkins Medicine Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.5.5 Johns Hopkins Medicine Recent Development
11.6 Mayo Clinic
11.6.1 Mayo Clinic Company Detail
11.6.2 Mayo Clinic Business Overview
11.6.3 Mayo Clinic Primary Ovarian Insufficiency Therapy Introduction
11.6.4 Mayo Clinic Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.6.5 Mayo Clinic Recent Development
11.7 Baptist Health
11.7.1 Baptist Health Company Detail
11.7.2 Baptist Health Business Overview
11.7.3 Baptist Health Primary Ovarian Insufficiency Therapy Introduction
11.7.4 Baptist Health Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.7.5 Baptist Health Recent Development
11.8 Indira IVF
11.8.1 Indira IVF Company Detail
11.8.2 Indira IVF Business Overview
11.8.3 Indira IVF Primary Ovarian Insufficiency Therapy Introduction
11.8.4 Indira IVF Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.8.5 Indira IVF Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details